Bionx Implants' CEO Gerard Carlozzi Talks to The Wall Street Transcript.Business Editors NEW YORK--(BUSINESS WIRE)--June 19, 2001 The Wall Street Transcript has published an in-depth interview with Gerard Carlozzi, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bionx Implants (Nasdaq:BINX), in which he talks at length about the company's future. The entire 2,700-word interview is available online at http://www.twst.com/info/info375.htm. Carlozzi gives an overview of the company. "Bionx Implants was founded based on a core process technology for self-reinforced polymer products. The company has an operation in Finland, where the company's core process technologies were developed. The self-reinforced polymer technology enhances the performance of resorbable polymers, increasing strength, room temperature malleability malleability, property of a metal describing the ease with which it can be hammered, forged, pressed, or rolled into thin sheets. Metals vary in this respect; pure gold is the most malleable. Silver, copper, aluminum, lead, tin, zinc, and iron are also very malleable. and uniform molecular weight distribution, improving performance and biocompatibility biocompatibility the quality of not having toxic or injurious effects on biological systems. biocompatibility 1. The extent to which a foreign, usually implanted, material elicits an immune or other response in a recipient 2. for use in medical applications." Carlozzi explains, "In the next three years, our plan is to continue to build and strengthen our sports medicine sports medicine, branch of medicine concerned with physical fitness and with the treatment and prevention of injuries and other disorders related to sports. Knee, leg, back, and shoulder injuries; stiffness and pain in joints; tendinitis; "tennis elbow"; and business and to be a full-line competitor in that area. The second piece of our strategy is to expand and apply the same strategy to our orthopedic orthopedic /or·tho·pe·dic/ (-pe´dik) pertaining to the correction of deformities of the musculoskeletal system; pertaining to orthopedics. trauma business, where we can continue to grow and expand the product line. We will use our core technology as a key component of our strategy, but we will also license other technology platforms that allow us to participate in a broader portion of the market than we currently do. We will continue to pursue strategic partnerships in areas outside of orthopedics orthopedics (ôrthəpē`dĭks), medical specialty concerned with deformities, injuries, and diseases of the bones, joints, ligaments, tendons, and muscles. , which will enable us to get market coverage and bring our products to those markets." Looking forward, Carlozzi states, "I think Bionx would be a good investment now. As we continue to execute our plan, establish sales growth and profitability, as well as establish our strategic partnerships that will infuse in·fuse v. 1. To steep or soak without boiling in order to extract soluble elements or active principles. 2. To introduce a solution into the body through a vein for therapeutic purposes. both cash and the ability to reach the marketplace, the value of the stock will increase over time." This interview is part of a Medical Technology Issue available at http://www.twst.com/info/info375.htm or by calling 212/952-7433. The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion